PROGRAM

REGISTRATION FEES

LOCATION & HOTEL INFO

Sign in with your ALDA account to register. Please contact us if you need assistance.

From Data to Discovery: Harnessing the Power of Multi-Omics

 

Dr. Mike Snyder – a leading expert in the field of genomics and personalized medicine – will present a comprehensive overview of the multi-omics landscape. This session will explore the relevance of multi-omics to enhancing our understanding of complex biological systems and diseases, offering insights into how this integrative approach can lead to more precise and predictive healthcare solutions. Dr. Snyder will also discuss the impact of multi-omics on drug development, disease diagnosis, and personalized treatment plans, highlighting practical applications that could benefit executive members and their companies.

 

Dr. Michael Snyder is the Stanford W. Ascherman Professor and Chair of the Genetics Department at Stanford Medicine, leading the Center for Genomics and Personalized Medicine since 2009. Under his leadership, Stanford has been top-ranked in Genetics, Genomics, and Bioinformatics for the past decade. A pioneer in personalized medicine, Dr. Snyder’s work in longitudinal baseline profiling and “omic” technologies has advanced precision medicine. His co-founded companies have raised $242 million in venture capital, exceeding $6 billion in value. He also serves on several corporate boards.

Revolutionizing Disease Understanding with Multi-Omics Research

 

Dr. Gary Patti, a renowned expert in metabolomics and key member of the NIH Multi-Omics for Health and Disease Consortium, will discuss the transformative potential of multi-omics research. This NIH consortium advances the generation and analysis of multi-omics data for human health research. As principal investigator of this consortium, Dr. Patti leads a central production center that functions as a hub for multi-omics analyses for materials from consortium members at each of six disease study sites identified by the NIH. Dr. Patti will share insights into how these efforts are revolutionizing disease understanding, with significant implications for ALDA member companies.

 

Gary J. Patti, PhD, is a leading researcher in the field of metabolomics and the Michael and Tana Powell Professor at Washington University in St. Louis, where he holds appointments in the department of chemistry and the department of medicine. Dr. Patti’s research focuses on developing and applying both mass spectrometry-based and NMR-based metabolomics technologies to enhance our understanding of human health. Dr. Patti is also founder of Panome Bio and has helped advance the field of metabolomics through the development of gold-standard software tools, commercial benchmarking kits, and NIH-led trials.

Deciphering Complex Biological Data: AI-Driven Approaches in Multi-Omics

 

Dr. Russ Altman, a distinguished professor at Stanford University and a pioneer in the field of bioinformatics, will delve into the intersection of artificial intelligence and multi-omics during his session. Drawing from his wide-ranging expertise, attendees can anticipate gaining invaluable insights into the transformative potential of AI-driven approaches in deciphering complex biological data. Don’t miss this opportunity to explore the cutting-edge applications of AI in multi-omics analysis with one of the foremost experts in the field.

 

Professor Russ Altman of Stanford University specializes in bioengineering, genetics, medicine, and computer science, focusing on the application of computing and informatics to medicine. His research explores drug actions at various biological levels and the impact of genetic variation on drug response. Altman has received numerous accolades, including the U.S. Presidential Early Career Award, and serves on the NIH Director’s Advisory Committee. He founded the PharmGKB knowledge base and advises pharmacogenomics companies.

Multi-Omics Integration in Drug Discovery & Development

 

Explore the transformative power of multi-omics in enhancing our understanding of human biology and its implications for health and disease over time. This session will delve into the innovative applications of multi-omics in drug discovery and development, highlighting its growing impact on the ALDA member community. Attendees will gain insights into the practical implications of multi-omics technologies for the industry and their businesses.

 

Dr. Mo Jain is a physician-scientist with an extensive background spanning two decades in medicine, physiology, mass spectrometry, and large-scale human discovery. Formerly the director of the Jain Laboratory at the University of California San Diego, Dr. Jain founded Sapient in 2021 with the ambitious goal of revolutionizing drug discovery through human data that extends beyond the genome.